Lupin Q2 FY23 revenue up 3.9%; Profit down 71%
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
The company has reported total income of Rs.77.0791 crores during the period ended December 31, 2022 as compared to Rs.69.9191 crores during the period ended December 31, 2021.
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure
Subscribe To Our Newsletter & Stay Updated